A Phase 4 interventional study of RFB002 and Dexamethasone in Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 37 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-17.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing ranibizumab in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. Ranibizumab · Retinal Vein Occlusion.
Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, this one is the 12th largest by enrollment, is one of 5 that started in 2012, is one of 13 in phase 4, and was the 25th registered.
289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
Browse Retinal Vein Occlusion studies →None of the 47 studies testing ranibizumab in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 12 · Phase 3 14 · Phase 4 13
First in 2006; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.
Median enrollment 56 across the 47 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 47 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
20 studies in Retinal Vein Occlusion by Novartis: none open now, none under way, none of them phase 3. Of 20 finished, 14 (70%) have results posted.
Among the 20 studies in Retinal Vein Occlusion by Novartis, this one is the 10th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2012, is one of 4 in phase 4, and was the 7th registered.
Novartis’s Retinal Vein Occlusion studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 20 in Retinal Vein Occlusion:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is intended to characterize the clinical benefit regarding safety and efficacy of a long term treatment with Lucentis in comparison with Ozurdex over an additional 6 months and a 3-month follow-up period, following the initial 6-month treatment in the respective core studies CRFB002EDE17 (NCT01396057) and CRFB002EDE18 (NCT01396083).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
who were menstruating and capable of becoming pregnant* and not practicing a medically approved method of (Pearl Index \<1**)*** during and up to at least 4 weeks after the end of treatment. A negative pregnancy test (serum) for all women and for girls entering menarche was required with sufficient lead time before randomization
definition of : 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy
examples of particularly reliable methods with Pearl Index (PI) \<1, according to guidelines of "Deutsche Gesellschaft für Gynäkologie und Geburtshilfe":
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The PRN injection scheme applied in the core study will also be followed during this extension study: Patients should be monitored monthly (starting at V1E) for VA and treatment is to be resumed when monitoring indicates loss of VA due to disease activity. Monthly injections should then be administered until stable VA is reached again for 3 consecutive monthly assessments (implying a minimum of 2 injections during stable VA). The interval between 2 doses should not be shorter than 1 month
Biological: RFB002
A PRN re-treatment scheme will be applied for the Ozurdex arm during this extension study, i.e. patients may receive an implant at V1E or later as needed: Patients should be monitored monthly and if there is a decline from stable VA stability due to macular edema patients will receive another intravitreal implant. (700 µg; long acting release (LAR)) given that in the opinion of the investigator the patient would benefit from the re-treatment. However, a minimum period of 5 months in between implantations is required.
Drug: Dexamethasone
0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. Each vial contained ranibizumab in an aqueous solution (pH 5.5) with histidine, trehalose and polysorbate 20.
Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only. Dexamethasone had to be stored according to label instructions and it had to be kept in a secure locked facility
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
The number of participants who experienced Adverse events, serious AE and death
Time frame: 6 months
Raw Mean Best Corrected Visual Acuity (BCVA) by Treatment Group
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. The range of BCVA (EDTRS) is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement
Time frame: Baseline, 6 months and 12 months
Percentage of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters at Month 12 Compared to Baseline
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who were gaining/losing ≥15, 10 or 5 more letters of visual acuity at month 12 as compared with baseline
Time frame: 12 month
Change in Central Subfield Thickness (CSRT) From Baseline to Month 12
High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.
Time frame: Baseline , Month 12
Change of Foveal Center Point Thickness (FCPT) From Baseline to Month 12
FCPT (foveal center point thickness) was assessed by central reading center to ensure error- corrected measurements of retinal thickness and volumes,
Time frame: Baseline, Month 12
Change in Mean Visual Function Questionnaire (VFQ-25)
The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function.
Time frame: Baseline, 12 months
Change in SF-36 Summary Scores
The SF-36 measures the impact of disease on overall quality of life and consists of eight subscales (physical function, pain, general and mental health, vitality, social function, physical and emotional health) which can be aggregated to derive a physical-component summary score and a mental-component summary score. Scores for each subscale range from 0 to 10, and the composite scores range from 0 to 100, with higher scores indicating better health. A positive change from Baseline score indicates improvement in quality of life.
Time frame: Baseline, month 12
Change in Euro Quality of Life Questionnaire (EQ-5D) VAS Summary Scores
The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health outcomes related to mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Participants self-rate their health on a visual, vertical analogue scale from 0 to 100 where the endpoints are labeled "Best imaginable health state" (100) and "worst imaginable health state" (0).
Time frame: Baseline, month 12
Time to the First Retreatment of Both Treatment Arms
Time to the first retreatment
Time frame: 6 months
A total of 140 patients with (BRVO) completed the core study CRFB002EDE17, and 127 patients with (CRVO) completed the core study CRFB002EDE18. 92 patients with BRVO and 83 patients with CRVO were enrolled into the extension study. A total of 175 patients (113 in the ranibizumab group and 62 in the dexamethasone group) were enrolled
| Milestone | Ranibizumab (BRVO) | Dexamethasone (BRVO) | Ranibizumab (CRVO) | Dexamethasone (CRVO) |
|---|---|---|---|---|
| Started | 52 | 40 | 61 | 22 |
| Completed | 51 | 33 | 57 | 20 |
| Not completed | 1 | 7 | 4 | 2 |
| Withdrew: Lack of efficacy | 0 | 5 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 | 1 | 1 |
| Withdrew: Administrative problems | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
The number of participants who experienced Adverse events, serious AE and death
| Participants | Ranibizumab (BRVO) | Dexamethasone (BRVO) | Ranibizumab (CRVO) | Dexamethasone (CRVO) |
|---|---|---|---|---|
| Adverse event | 35 | 28 | 45 | 16 |
| Serious adverse event | 2 | 3 | 6 | 1 |
| Death | 0 | 0 | 0 | 0 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. The range of BCVA (EDTRS) is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement
| Letters read correctly | Ranibizumab (BRVO) | Dexamethasone (BRVO) | Ranibizumab (CRVO) | Dexamethasone (CRVO) |
|---|---|---|---|---|
| Baseline | 56.8 ± 10.0 | 58.3 ± 10.8 | 53.8 ± 15.7 | 53.2 ± 16.1 |
| Month 6 | 77.9 ± 10.6 | 69.2 ± 11.9 | 72.6 ± 13.5 | 64.1 ± 24.0 |
| Month 12 | 79.0 ± 10.1 | 70.6 ± 13.9 | 72.6 ± 15.8 | 66.6 ± 22.3 |
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who were gaining/losing ≥15, 10 or 5 more letters of visual acuity at month 12 as compared with baseline
| Percentage of participants | Ranibizumab (BRVO) | Dexamethasone (BRVO) | Ranibizumab (CRVO) | Dexamethasone (CRVO) |
|---|---|---|---|---|
| Gain≥15 letters | 80.8 | 50.0 | 58.3 | 45.5 |
| Gain ≥10 letters | 88.5 | 65.0 | 75.0 | 68.2 |
| Gain ≥5 letters | 100.0 | 80.0 | 86.7 | 77.3 |
| Loss of ≥15 letters | 0.0 | 7.5 | 0.0 | 4.5 |
| Loss of ≥10 letters | 0.0 | 10.0 | 0.0 | 4.5 |
| Loss of ≥5 letters | 0.0 | 10.0 | 3.3 | 4.5 |
High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.
| um | Ranibizumab (BRVO) | Dexamethasone (BRVO) | Ranibizumab (CRVO) | Dexamethasone (CRVO) |
|---|---|---|---|---|
| Change in Central Subfield Thickness (CSRT) From Baseline to Month 12 | -288.1 ± 180.6 | -211.5 ± 199.3 | -374.6 ± 239.8 | -360.3 ± 260.2 |
FCPT (foveal center point thickness) was assessed by central reading center to ensure error- corrected measurements of retinal thickness and volumes,
| um | Ranibizumab (BRVO) | Dexamethasone (BRVO) | Ranibizumab (CRVO) | Dexamethasone (CRVO) |
|---|---|---|---|---|
| Change of Foveal Center Point Thickness (FCPT) From Baseline to Month 12 | -341.8 ± 226.2 | -252.6 ± 197.9 | -439.4 ± 279.8 | -432.3 ± 245.8 |
The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function.
| Scores on a scale | Ranibizumab (BRVO) | Dexamethasone (BRVO) | Ranibizumab (CRVO) | Dexamethasone (CRVO) |
|---|---|---|---|---|
| Overall Composite | 8.1 ± 10.6 | 5.5 ± 11.3 | 9.1 ± 15.5 | 10.0 ± 15.9 |
| General Health | -1.4 ± 15.2 | 6.3 ± 18.6 | 1.7 ± 18.9 | 5.7 ± 20.3 |
| General Vision | 15.0 ± 16.7 | 9.5 ± 16.3 | 20.0 ± 17.7 | 13.6 ± 23.4 |
| Ocular Pain | 5.3 ± 15.7 | 5.3 ± 13.8 | 4.2 ± 20.8 | 3.4 ± 15.0 |
| Near Activities | 13.3 ± 18.9 | 10.8 ± 20.6 | 12.3 ± 20.5 | 12.3 ± 23.2 |
| Distance Activities | 8.9 ± 17.5 | 5.6 ± 15.3 | 7.8 ± 18.3 | 8.3 ± 23.4 |
| Social Functioning | 3.4 ± 16.8 | 2.2 ± 12.0 | 3.3 ± 16.7 | 2.8 ± 21.1 |
| Mental Health | 10.2 ± 14.9 | 2.9 ± 20.4 | 10.7 ± 21.7 | 15.1 ± 18.3 |
| Role Difficulties | 4.8 ± 26.8 | 10.6 ± 20.5 | 14.6 ± 29.9 | 24.4 ± 27.8 |
| Dependency | 3.2 ± 9.2 | 0.4 ± 16.6 | 5.1 ± 16.7 | 4.4 ± 12.8 |
| Driving (BRVO n=44,31) (CRVO n=42,16) | 11.7 ± 23.9 | 4.8 ± 21.3 | 14.2 ± 24.6 | 17.7 ± 25.1 |
| Color Vision(BRVO n=52,39) | 0.5 ± 10.5 | 1.9 ± 10.6 | 0.4 ± 17.5 | -1.1 ± 14.4 |
| Peripheral Vision(BRVO n=51,40) | 10.3 ± 24.1 | 6.9 ± 23.3 | 11.7 ± 25.0 | 14.8 ± 22.7 |
The SF-36 measures the impact of disease on overall quality of life and consists of eight subscales (physical function, pain, general and mental health, vitality, social function, physical and emotional health) which can be aggregated to derive a physical-component summary score and a mental-component summary score. Scores for each subscale range from 0 to 10, and the composite scores range from 0 to 100, with higher scores indicating better health. A positive change from Baseline score indicates improvement in quality of life.
| Score on a scale | Ranibizumab (BRVO) | Dexamethasone (BRVO) | Ranibizumab (CRVO) | Dexamethasone (CRVO) |
|---|---|---|---|---|
| Physical Component(BRVO n=50,39) (CRVO n=58,20) | 1.6 ± 5.0 | 0.2 ± 7.0 | -1.1 ± 8.2 | 1.3 ± 7.2 |
| Mental Component (BRVO n=50,39) (CRVO n=58,20) | 3.3 ± 9.7 | 2.1 ± 13.2 | 2.1 ± 9.3 | 2.4 ± 12.4 |
The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health outcomes related to mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Participants self-rate their health on a visual, vertical analogue scale from 0 to 100 where the endpoints are labeled "Best imaginable health state" (100) and "worst imaginable health state" (0).
| Score on a scale | Ranibizumab (BRVO) | Dexamethasone (BRVO) | Ranibizumab (CRVO) | Dexamethasone (CRVO) |
|---|---|---|---|---|
| Change in Euro Quality of Life Questionnaire (EQ-5D) VAS Summary Scores | 3.3 ± 15.2 | 2.6 ± 16.9 | 1.5 ± 16.4 | 0.2 ± 20.4 |
Time to the first retreatment
| Days | Ranibizumab (BRVO) | Dexamethasone (BRVO) | Ranibizumab (CRVO) | Dexamethasone (CRVO) |
|---|---|---|---|---|
| Time to the First Retreatment of Both Treatment Arms | 37 (3 to 56) | NA (328 to NA) | 62 (5 to 67) | NA (309 to NA) |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab (BRVO) | — | 2/52 (3.8%) | 35/52 (67.3%) |
| Dexamethasone (BRVO) | — | 3/40 (7.5%) | 28/40 (70%) |
| Ranibizumab (CRVO) | — | 6/61 (9.8%) | 45/61 (73.8%) |
| Dexamethasone (CRVO) | — | 1/22 (4.5%) | 16/22 (72.7%) |
| Event | Ranibizumab (BRVO) | Dexamethasone (BRVO) | Ranibizumab (CRVO) | Dexamethasone (CRVO) |
|---|---|---|---|---|
| RETINAL DETACHMENT (Study eye)Eye disorders | 0/52 | 0/40 | 0/61 | 1/22 |
| VITREOUS HAEMORRHAGE (Study eye)Eye disorders | 0/52 | 0/40 | 1/61 | 1/22 |
| INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders | 1/52 | 1/40 | 0/61 | 0/22 |
| ROTATOR CUFF SYNDROMEMusculoskeletal and connective tissue disorders | 0/52 | 1/40 | 0/61 | 0/22 |
| LUMBAR RADICULOPATHYNervous system disorders | 0/52 | 1/40 | 0/61 | 0/22 |
| PSORIASISSkin and subcutaneous tissue disorders | 0/52 | 1/40 | 0/61 | 0/22 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 1/52 | 0/40 | 0/61 | 0/22 |
| GLAUCOMA (Fellow eye)Eye disorders | 0/52 | 0/40 | 1/61 | 0/22 |
| GLAUCOMA (Study eye)Eye disorders | 0/52 | 0/40 | 1/61 | 0/22 |
| IRIS NEOVASCULARISATION (Study eye)Eye disorders | 0/52 | 0/40 | 1/61 | 0/22 |
| Event | Ranibizumab (BRVO) | Dexamethasone (BRVO) | Ranibizumab (CRVO) | Dexamethasone (CRVO) |
|---|---|---|---|---|
| INTRAOCULAR PRESSURE INCREASED (Study eye)Investigations | 3/52 | 10/40 | 3/61 | 4/22 |
| MACULAR OEDEMA (Study eye)Eye disorders | 9/52 | 3/40 | 14/61 | 3/22 |
| NASOPHARYNGITISInfections and infestations | 9/52 | 3/40 | 12/61 | 3/22 |
| EYE PAIN (Study eye)Eye disorders | 4/52 | 0/40 | 7/61 | 4/22 |
| CONJUNCTIVAL HAEMORRHAGE (Study eye)Eye disorders | 2/52 | 7/40 | 3/61 | 3/22 |
| OCULAR HYPERAEMIA (Study eye)Eye disorders | 7/52 | 3/40 | 4/61 | 3/22 |
| VISUAL ACUITY REDUCED (Study eye)Eye disorders | 4/52 | 4/40 | 8/61 | 1/22 |
| LACRIMATION INCREASED (Study eye)Eye disorders | 6/52 | 2/40 | 2/61 | 2/22 |
| OCULAR DISCOMFORT (Study eye)Eye disorders | 2/52 | 4/40 | 1/61 | 0/22 |
| RETINAL ISCHAEMIA (Study eye)Eye disorders | 5/52 | 4/40 | 2/61 | 0/22 |
| Age, Continuous(Years) | Ranibizumab | Dexamethasone | Total |
|---|---|---|---|
| Mean | 65.6 ± 9.9 | 63.3 ± 10.3 | 64.8 ± 10.1 |
| Sex: Female, Male(Participants) | Ranibizumab | Dexamethasone | Total |
|---|---|---|---|
| Female | 64 | 26 | 90 |
| Male | 49 | 36 | 85 |
The record gives a start of May 2012, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab